Synthesis and evaluation of 177Lu-labeled anti-EGFR Fab antibody for lung cancer

被引：0
|
作者：
Li, Yuan-Yuan [1 ,2 ]
Yu, Jia-Yan [1 ,2 ]
Wang, Tao [1 ,2 ]
Wang, Jing [2 ,3 ]
Zhao, Peng [2 ,3 ]
Yang, Xia [2 ,3 ]
Wei, Hong-Yuan [2 ,4 ]
Chen, Yue [1 ,4 ]
机构：
[1] Southwest Med Univ, Dept Nucl Med, Affiliated Hosp, Luzhou 646000, Peoples R China
[2] China Acad Engn Phys, Inst Nucl Phys & Chem, Mianyang 621900, Peoples R China
[3] Lab Targeted Radiopharmaceut Creat, Mianyang 621900, Peoples R China
[4] Key Lab Nucl Med & Mol Imaging Sichuan Prov, Luzhou 646000, Peoples R China
来源：
JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY | 2025年
基金：
中国国家自然科学基金;
关键词：
Fab fragments; Lutetium-177; Anti-EGFR antibody; Biodistribution; Lung cancer; SQUAMOUS-CELL CARCINOMA; TARGETED THERAPY; RADIOIMMUNOTHERAPY; BIODISTRIBUTION; NECK; HEAD;
D O I：
10.1007/s10967-025-10030-4
中图分类号：
O65 [分析化学];
学科分类号：
070302 ; 081704 ;
摘要：
Fab fragments obtained via enzymatic digestion of full-length antibodies or by gene recombination technology have smaller molecular weight and greater penetration ability. Those advantages make it uniquely suited to deliver radionuclides. In this study, we prepared a Fab fragment from the anti-EGFR antibody Cetuximab and labeled it with 177Lu. The binding activity in vitro and biodistribution in vivo of [177Lu]Lu-DOTA-Fab-Cetuximab were investigated. The [177Lu]Lu-labeled Fab fragment showed improved tumor penetration and faster blood clearance compared to the full-length antibody.
引用
收藏
页码：2139 / 2149
页数：11
相关论文
共 50 条
  • [31] Preclinical evaluation of the theranostic potential of 89Zr/177Lu-labeled anti-TROP-2 antibody in triple-negative breast cancer model
    Yitian Wu
    Tuo li
    Xianzhong Zhang
    Hongli Jing
    Fang Li
    Li Huo
    EJNMMI Radiopharmacy and Chemistry, 9
  • [32] Pretargeted radioimmunotherapy of an anti-CEA bispecific antibody and 177Lu-labeled peptide: a phase I study in patients with advanced colorectal cancer
    Schoffelen, Rafke
    Boerman, Otto C.
    Goldenberg, David M.
    Sharkey, Robert M.
    Herpen, Carla M. L.
    Chang, Chien-Hsing
    Franssen, Gerben M.
    McBride, William J.
    Rossi, Edmund A.
    van der Graaf, Winette T. A.
    Oyen, Wim J. G.
    CANCER RESEARCH, 2012, 72
  • [33] Potentials of 177Lu-labeled sodium pyrophosphate (177Lu-PYP) as a new therapeutic radiopharmaceutical for the treatment of bone cancer
    Abbasi, Imtiaz Ahmed
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2013, 246
  • [34] Towards clinical translation of a novel antibody-based 177Lu-labeled radiopharmaceutical for treatment of anaplastic thyroid cancer
    Mortensen, A.
    Berglund, H.
    Shojai, T. Mohajer
    Persson, H. Lotsholm
    Stenman, A.
    Jha, P.
    Juhlin, C.
    Bernhardt, P.
    Zedenius, J.
    Frejd, F.
    Nestor, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S116 - S116
  • [35] Synthesis and Preliminary Biological Evaluation of 177Lu-Labeled Polyhydroxamic Acid Microparticles Toward Therapy of Hepatocellular Carcinoma
    Pandey, Usha
    Subramanian, Suresh
    Shaikh, Samina
    Gamre, Naresh
    Kumar, Sanjukta
    Dash, Ashutosh
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2019, 34 (05) : 306 - 315
  • [36] In vivo evaluation of 177Lu-labeled h11B6, a humanized antibody for hK2 targeting in prostate cancer
    Timmermand, Oskar Vilhelmsson
    Larsson, Erik
    Strand, Sven-Erik
    Thuy Tran
    JOURNAL OF NUCLEAR MEDICINE, 2014, 55
  • [37] The Therapeutic Efficacy of 177Lu-labeled Theranostic Polymeric Nanoparticles (177Lu-PNPs) in the Treatments of Head and Neck Cancer
    Hsieh, Hsin-Hua
    Chen, Chuan-Lin
    Wu, Chun-Yi
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [38] Theranostic role of 89Zr- and 177Lu-labeled aflibercept in breast cancer
    Qi Yang
    Zhao Chen
    Yongkang Qiu
    Wenpeng Huang
    Tianyao Wang
    Lele Song
    Xinyao Sun
    Cuicui Li
    Xiaojie Xu
    Lei Kang
    European Journal of Nuclear Medicine and Molecular Imaging, 2024, 51 : 1246 - 1260
  • [39] Anti-EGFR antibody conjugated silica nanoparticles as probes for lung cancer detection
    Wan, Jun
    Wu, Wei
    Zhang, Renquan
    Liu, Shandong
    Huang, Yunlong
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2017, 14 (04) : 3407 - 3412
  • [40] Prospects of medium specific activity 177Lu in targeted therapy of prostate cancer using 177Lu-labeled PSMA inhibitor
    Chakraborty, Sudipta
    Chakravarty, Rubel
    Shetty, Priyalata
    Vimalnath, K. V.
    Sen, Ishita B.
    Dash, Ashutosh
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2016, 59 (09): : 364 - 371
12345